JEOL Ltd.
JELLF
Other OTC40.78
USD
- -
- -
CIK
0002089509
ISIN
JP3735000006
Return %
Stock
S&P500
1Y
22.83
18.86
3Y
16.31
64.57
5Y
38.00
71.65
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Izumi Oi
- Full Time Employees
- 3,731
- Sector
- Technology
- Industry
- Hardware, Equipment & Parts
- Address
- 3-1-2, Musashino Akishima TY Japan 196-8558
- IPO Date
- Aug 4, 2020
- CIK
- 0002089509
- Website
- jeol.co.jp
- Similar Companies
- Business
- JEOL Ltd. (TSE: 6951) develops and manufactures scientific and metrology instruments, semiconductor and industrial equipment, and medical equipment. The company operates four main business segments: electron optics, which produces transmission electron microscopes, scanning electron microscopes, focused ion beam systems, electron probe micro analyzers, photoelectron spectrometers, auger micro probes, soft X-ray emission spectrometers, energy-dispersive X-ray fluorescence spectrometers, electron diffractometers and related peripherals; analytical instruments, including nuclear magnetic resonance spectrometers, electron spin resonance spectrometers and mass spectrometers such as MALDI time-of-flight, gas chromatograph-mass and liquid chromatograph-mass types; semiconductor equipment featuring electron beam lithography systems using variable shaped and spot beam technologies; industrial equipment comprising high power electron beam sources, deposition sources, plasma sources, powder feeders and electron beam metal 3D printers; and medical equipment centered on the BioMajesty series of clinical chemistry analyzers. JEOL maintains global operations with subsidiaries across North America, Europe and Asia, serving academic, industrial and research customers in fields such as nanotechnology, biotechnology, semiconductors, drug discovery and batteries. Founded in 1949 and headquartered at 3-1-2 Musashino, Akishima, Tokyo, the company employs around 3,600 people consolidated and reported sales of JPY197 billion for the fiscal year ended March 2025. Recent developments include the acquisition of Japan Superconductor Technology, Inc. (JASTEC) from Kobe Steel, finalized in early January 2025 to bolster superconducting wire and magnet capabilities; construction of new facilities at its Akishima main office and Yamagata plant announced in May 2025 under the Evolving Growth 2.0 medium-term plan to enhance productivity and smart factory operations; a March 2025 partnership with WEGO Shingene Medical Technology Co., Ltd. of China; and the September 2025 divestiture of its clinical chemistry medical equipment business to Sysmex Corporation, accompanied by the establishment of a dedicated medical equipment subsidiary.